Core Viewpoint - The market anticipates a year-over-year decline in Atkore Inc.'s earnings due to lower revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - Atkore is expected to report quarterly earnings of $2.05 per share, reflecting a decline of 49.8% year-over-year, with revenues projected at $699.9 million, down 11.7% from the previous year [3]. - The consensus EPS estimate has been revised down by 7.59% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, making it challenging to predict an earnings beat [10][11]. - The stock currently holds a Zacks Rank of 3, which does not strongly indicate a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Atkore exceeded the expected earnings of $1.50 per share by delivering $1.63, resulting in a surprise of +8.67% [12]. - Over the past four quarters, Atkore has beaten consensus EPS estimates twice [13]. Conclusion - While Atkore does not appear to be a strong candidate for an earnings beat, investors should consider other factors influencing stock performance ahead of the earnings release [16].

Core Insights - ArcBest reported revenue of $967.08 million for the quarter ended March 2025, a decrease of 6.7% year-over-year, and EPS of $0.51, down from $1.34 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $981.56 million by 1.48%, and the EPS was also below the consensus estimate of $0.52 by 1.92% [1] Financial Performance Metrics - ArcBest's shares have declined by 16.3% over the past month, contrasting with the Zacks S&P 500 composite's decline of 0.8%, indicating potential underperformance in the near term with a Zacks Rank 4 (Sell) [3] - The Asset-Light Operating Ratio was reported at 101.2%, slightly better than the average estimate of 101.6% from three analysts [4] - The Asset-Based Operating Ratio was 95.9%, aligning closely with the average estimate of 95.7% from three analysts [4] - Asset-Based revenues were reported at $646.29 million, a decrease of 3.8% year-over-year, compared to the average estimate of $647.61 million from four analysts [4] - Asset-Light revenues were reported at $356.01 million, down 10.2% year-over-year, against the average estimate of $366.20 million from four analysts [4] - The reported revenue from Other and eliminations was -$35.23 million, worse than the average estimate of -$31.14 million from three analysts, but showed a year-over-year improvement of 12.2% [4]

Image Source: Zacks Energy supermajor Chevron Corporation (CVX) is slated to release its first-quarter 2025 results on May 2, before market open. The Zacks Consensus Estimate for the to-be-reported quarter's earnings per share (EPS) and revenues is pegged at $2.30 per share and $47.9 billion, respectively. The earnings estimates for the to-be-reported quarter have been revised downward by 7.6% over the past 30 days. The bottom-line projection indicates a decline of 21.5% from the year-ago reported number. T ...

Core Viewpoint - Kellanova is expected to report a decline in quarterly earnings and revenues, with analysts predicting earnings of $0.98 per share and revenues of $3.13 billion, reflecting decreases of 3% and 2.1% year-over-year respectively [1] Financial Estimates - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating analysts' reassessment of their forecasts [1] - Analysts project 'Net sales- Latin America' at $285.85 million, a decrease of 9% from the prior-year quarter [4] - 'Net sales- Europe' is estimated at $586.27 million, reflecting a decline of 2.1% year-over-year [4] - 'Net sales- North America' is expected to reach $1.66 billion, indicating a decrease of 1.5% from the previous year [4] - 'Net sales- AMEA' is forecasted at $571.91 million, suggesting a year-over-year decline of 4.7% [5] Growth Metrics - Total reported growth for Latin America is expected to be -8.9%, down from 10.9% in the same quarter last year [5] - 'Net sales - Latin America - Forex impact - YoY change' is projected at -12.4%, compared to 5.7% a year ago [5] - 'Net sales - AMEA - Price / mix impact - YoY change' is estimated at 11.7%, down from 19.4% in the same quarter last year [6] - 'Net sales - Europe - Price / mix impact - YoY change' is expected to be 2.3%, compared to 9.5% a year ago [6] - 'Net sales - North America - Price / mix impact - YoY change' stands at -0.8%, down from 4.8% year-over-year [7] - 'Net sales - Consolidated - price / mix impact - YoY change' is projected at 2.4%, compared to 8.5% in the previous year [7] Profitability Estimates - 'Adjusted Operating Profit / (loss)- Latin America' is expected to be $20.94 million, down from $25 million year-over-year [8] - 'Adjusted Operating Profit / (loss)- Europe' is projected at $98.12 million, slightly up from $98 million in the same quarter last year [8] Stock Performance - Kellanova shares have experienced a change of -0.1% over the past month, compared to a -0.8% move in the Zacks S&P 500 composite [9] - The company holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market [9]

Core Viewpoint - Block (XYZ) is expected to report quarterly earnings of $0.88 per share, a 3.5% increase year-over-year, with revenues projected at $6.18 billion, reflecting a 3.8% year-over-year growth [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been revised upward by 0.4%, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts project 'Revenue- Hardware' at $32.20 million, a decrease of 0.9% from the previous year [5]. - 'Revenue- Subscription and services-based' is expected to reach $1.89 billion, an increase of 12.4% year-over-year [5]. - 'Revenue- Transaction-based' is forecasted at $1.59 billion, reflecting a 4.9% year-over-year increase [5]. - 'Revenue- Bitcoin' is estimated at $2.70 billion, a decline of 1.2% from the prior year [6]. - 'Revenue- Square- Total' is projected at $1.86 billion, indicating a 7.8% increase year-over-year [6]. - 'Revenue- Square- Subscription and services-based' is expected to reach $338.32 million, a 14.2% increase from the previous year [7]. - 'Revenue- Cash App- Bitcoin' is projected at $2.63 billion, a decrease of 3.8% year-over-year [8]. - 'Revenue- Cash App- Transaction-based' is estimated at $94.50 million, reflecting a decline of 13.5% from the prior year [8]. Gross Payment Volume - The estimated 'Gross Payment Volume (GPV)' is $58.01 billion, up from $50.50 billion reported in the same quarter last year [9]. Stock Performance - Over the past month, Block shares have returned +7.3%, contrasting with the Zacks S&P 500 composite's -0.8% change [9].

Core Viewpoint - MetLife, Inc. is expected to report first-quarter 2025 results on April 30, with earnings estimated at $1.99 per share and revenues at $18.21 billion, reflecting year-over-year growth of 8.7% and 7% respectively [1] Financial Estimates - The Zacks Consensus Estimate for MetLife's revenues for the current year is $74.94 billion, indicating a year-over-year increase of 2.6% [2] - The consensus estimate for current-year EPS is $9.11, suggesting a year-over-year jump of approximately 12.33% [2] - In the last four quarters, MetLife beat the consensus estimate once, met it once, and missed twice, with an average surprise of negative 1.5% [2] Earnings Prediction - The current model does not predict a definitive earnings beat for MetLife, as it has an Earnings ESP of +0.24% but a Zacks Rank of 4 (Sell) [3][4] Factors Influencing Q1 Results - Rising adjusted group benefits revenues are anticipated to positively impact MetLife's first-quarter results, particularly from improved operations in international markets, especially Asia and Latin America [5] - The Zacks Consensus Estimate for total adjusted group benefits suggests a 2.3% increase from the prior-year quarter, driven by profits from Asia and Latin America [6] - Adjusted earnings from the domestic business are expected to grow by 10.5% year-over-year in the first quarter [7] Challenges - Rising costs and expenses may partially offset profit growth in the upcoming quarter, with net investment income consensus pegged at $5.3 billion, indicating a 3% decline year-over-year [9]

Core Viewpoint - Williams Companies, Inc. is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending March 2025, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate for quarterly earnings is $0.57 per share, reflecting a year-over-year decrease of 3.4%, while revenues are projected to reach $3.14 billion, representing a 13.4% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 3.8%, indicating a reassessment by analysts regarding the company's earnings outlook [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for the company is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.35%, suggesting a bearish sentiment among analysts [10][11]. Historical Performance - In the last reported quarter, the company exceeded the expected earnings of $0.45 per share by delivering $0.47, achieving a surprise of +4.44%. Over the past four quarters, the company has consistently beaten consensus EPS estimates [12][13]. Investment Considerations - Despite the historical performance of beating estimates, the current combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict a positive earnings surprise for the upcoming report [11][16].

Analysts on Wall Street project that Wingstop (WING) will announce quarterly earnings of $0.84 per share in its forthcoming report, representing a decline of 14.3% year over year. Revenues are projected to reach $170.46 million, increasing 16.9% from the same quarter last year. The consensus EPS estimate for the quarter has been revised 1.8% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this ti ...

Core Insights - Analysts expect Organon (OGN) to report quarterly earnings of $0.92 per share, reflecting a year-over-year decline of 24.6% and revenues of $1.54 billion, down 4.9% from the previous year [1] - There has been a downward revision of 1.7% in the consensus EPS estimate over the last 30 days, indicating a reconsideration of initial forecasts by analysts [1][2] Revenue Estimates - Revenue from Women's Health for Nexplanon/Implanon NXT is projected at $236.63 million, showing a year-over-year increase of 7.6% [4] - The consensus estimate for Biosimilars Total revenue is $153.47 million, indicating a decline of 9.7% from the year-ago quarter [4] - Revenue for Women's Health from NuvaRing is estimated at $25.26 million, reflecting a significant decrease of 33.5% year-over-year [4] - Revenue from Women's Health for Follistim AQ is expected to be $55.48 million, marking a year-over-year increase of 20.6% [5] - U.S. revenue for Nexplanon/Implanon NXT is projected at $165.06 million, indicating a growth of 7.9% from the previous year [5] - Geographic Revenue from the U.S. is expected to reach $407.08 million, suggesting a year-over-year increase of 9.7% [6] - Revenue from Women's Health for U.S. NuvaRing is forecasted at $8.12 million, indicating a substantial decline of 49.2% from the year-ago quarter [6] - Revenue from Women's Health for U.S. Follistim AQ is estimated at $18.97 million, reflecting a significant increase of 72.4% year-over-year [6] - Revenue from Established Brands in the U.S. for Respiratory- Other is projected at $7.68 million, indicating a year-over-year increase of 9.8% [7] - Geographic Revenue from Other International is expected to be $25.18 million, reflecting a decline of 13.2% from the prior-year quarter [7] - Revenue from Established Brands International for Non-Opioid Pain, Bone and Dermatology- Other is estimated at $68.21 million, suggesting a slight increase of 0.3% year-over-year [8] - Revenue from Established Brands International for Non-Opioid Pain, Bone and Dermatology- Diprospan is projected at $30.94 million, indicating a year-over-year increase of 6.7% [8] Stock Performance - Over the past month, Organon shares have declined by 15.9%, compared to a 4.3% decline in the Zacks S&P 500 composite [8]

Core Viewpoint - Columbia Sportswear Company (COLM) is expected to report a decline in both revenues and earnings for the first quarter of 2025, with revenues estimated at $761.9 million, reflecting a 1.1% decrease year-over-year [1]. Revenue Expectations - The Zacks Consensus Estimate for first-quarter revenues is $761.9 million, indicating a 1.1% decrease from the previous year, aligning with the company's guidance of a 1-3% decline, projecting net sales between $749 million and $764 million [1][2]. - The decline in revenues is attributed to the absence of last year's unusually cold winter, which had temporarily boosted demand, and a return to normalized shipping patterns after accelerated shipments in the previous year [2]. Earnings Projections - The consensus estimate for first-quarter earnings per share is stable at 69 cents, representing a 2.8% decline from the year-ago period, with management guiding earnings between 62 cents and 70 cents per share [2]. - Columbia Sportswear has delivered an average earnings surprise of 36.7% over the trailing four quarters [2]. Market Conditions - The company is facing a challenging U.S. market characterized by softened consumer demand, although it has seen stronger performance internationally, particularly in China and the EMEA region [3]. Operating Margin Insights - The projected operating margin for the first quarter is between 5.4% and 6%, with a midpoint of 5.7%, which is a decrease of 10 basis points from the same quarter last year [4]. Strategic Initiatives - Columbia Sportswear's product innovation, ACCELERATE Growth Strategy, and cost-saving initiatives are expected to provide some support against the anticipated declines, with efforts to expand premium product lines and enhance marketing investments [5]. Earnings Prediction Model - The Zacks model does not predict an earnings beat for Columbia Sportswear this quarter, as it holds a Zacks Rank of 3 and an Earnings ESP of 0.00% [6].